MedTrace Logo

A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

NCT07545681 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-22

No results posted yet for this study

Summary

The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

Conditions

  • Malaria, Falciparum

Interventions

DRUG

GSK3772701 600 mg

A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.

DRUG

GSK3772701 900 mg

A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg.

DRUG

GSK3772701 150 mg

A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule.

DRUG

GSK3772701 400 mg

A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg.

DRUG

GSK3772701 50 mg

A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2027-07-22
Completion
2027-07-22

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07545681 on ClinicalTrials.gov